Skip to main content

Table 3 Characteristics of patients by age at the beginning of biologic treatment according to biologic compound, number of biologic drugs, and reasons for suspension

From: Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER

  < 16 Years ≥16 Years p Value
Number of patients 137 (29.2) 332 (70.8)  
Age at the beginning of biological treatment 9.0 [4.2] 30.2 [11.4] < 0.001
Years of disease progression 2.7 [3.1] 19.5 [2.1] < 0.001
Biologic compound
 Etanercept 81 (59.1) 123 (37.1) < 0.001
 Adalimumab 31 (21.6) 58 (17.5)
 Infliximab 9 (6.6) 134 (40.4)
 Tocilizumab 8 (5.8) 8 (2.4)
 Abatacept 5 (1.5)
 Anakinra 6 (4.4) 2 (0.6)
 Certolizumab 2 (1.5)
 Golimumab 2 (0.6)
Reason for suspension
 Inefficacy 26 (37.1) 80 (37.4) < 0.001
 Remission 18 (25.7) 17 (7.9)
 Adverse event 20 (28.6) 60 (28.0)
 Loss of tracking 4 (5.7) 20 (9.4)
 Pregnancy or gestational desire 13 (6.1)
 Other reasons 2 (2.9) 22 (10.3)
 Unknown 2 (0.9)
Number of biologic drugs
 1 drug 83 (60.6) 183 (55.1) 0.244
  > 1 drug 54 (39.4) 149 (44.9)
  2 27 (19.7) 67 (20.2)
  3 13 (9.5) 38 (11.5)
  4 11 (8.0) 12 (3.6)
  5 or more 3 (2.2) 32 (9.6)
  1. Data are expressed as mean [SD] or as number of patients (%). Chi-squared tests were used to compare distributions for categorical variables, and Student’s t tests were used for numerical variables